核苷类似物序贯疗法治疗慢性HBV携带者的疗效观察  

Observation on the effect of sequential use of nucleosides on chronic HBV carriers

作　　者：付小义[1] 彭雁忠[1] 汤炽良[1] 武敬[1] 

机构地区：[1]北京大学深圳医院感染性疾病科,广东深圳518036

出　　处：《中国热带医学》2007年第12期2214-2215,共2页China Tropical Medicine

摘　　要：目的观察核苷类似物序贯疗法对慢性HBV携带者的疗效。方法采用序贯疗法,口服拉米夫啶(LVD),6月后联合服用阿德福韦酯(ADV),2月后停服LVD,续用ADV12月,总疗程18月;用RT-PCR法测定患者抗病毒治疗前后血HBVDNA含量。结果经LVD、ADV序贯治疗后,所有慢性HBV携带者的血清HBV DNA水平都经历一段短暂下降过程之后,大多数又逐渐恢复到治疗前水平,只有少数(20%)慢性HBV携带者疗程结束后6月,其HBV DNA仍是低于检测下限值。结论核苷类似物序贯疗法可使少数(20%)慢性HBV携带者的血清HBV-DNA转阴。Objective To observe the effect of sequential use of nucleosides on chronic HBV carriers. Methods Sequential thereapy was used, lamivudinc （LVD） was firstly given to the patients, six months later LVD combined with adfovir dipivoxil （ADV） was used, then two months later LVD was no longer used and ADV was continued for 12 months with a total course of 18 months. The contents of HBVDNA in the patients before and after treatment was determined with RT-PCR, Results The level of HBVDNA in serum of all chronic HBV carriers was gradually returned to the levels before treatment after short period of drop. The level of HBVDNA was still kept at the lower limit 6 months after completion of the course in 20% of the chronic HBV carriers. Conclusion The serum HBVDNA become negative in 20% of chronic HBV carriers by using sequential therapy with nuceosides.

关 键 词：慢性HBV携带者 抗病毒治疗 拉米夫啶 阿德福韦酯 

分 类 号：R512.62[医药卫生—内科学]